2024 ICD-10-CM Diagnosis Code R39.89

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

• Abnormal angle of erection
• Abnormal sensation of bladder
• Abnormal urogenital discharge
• Absence of secondary sexual hair
• Always has an erection
• Bladder dysfunction
• Bladder pain
• Bladder tender
• Bladder volume - finding
• Blood clots in vagina
• Blood in vagina
• Calkin's sign
• Cervical excitation - finding
• Cervical excitation - finding
• Cervical excitation equivocal
• Cervical excitation present
• Cervical os open
• Cervical os patulous
• Chadwick's sign
• Dark yellow urine
• Decreased fertility
• Decreased fertility in male
• Discharge from female genitalia
• Dropping sensation- pelvic floor
• Ejaculation without an erection
• Ejaculation without arousal
• Ejaculation without orgasm
• Emission
• Erection too big
• Erection too easily aroused
• Erection when not aroused
• Erection with full bladder
• Excessive erection
• Fear of ejaculation
• Feeling of pressure in vagina
• Feeling of something coming down the vagina
• Female perineum red
• Finding of color of female perineum
• Finding of consistency of testes
• Finding of consistency of uterine cervix
• Finding of consistency of uterus
• Finding of contents of vagina
• Finding of device of vagina
• Finding of device of vagina
• Finding of device of vagina
• Finding of measures of bladder
• Finding of moistness of female perineum
• Finding of postcoital cervical mucus spermatozoa motility
• Finding of postcoital cervical mucus spermatozoa motility
• Finding of postcoital cervical mucus spermatozoa motility
• Finding of secondary sexual hair growth
• Finding of secondary sexual hair growth
• Finding of sensation of bladder
• Finding of sensation of cervix
• Finding of sensation of cervix
• Finding of shape of pregnant abdomen
• Finding of size of hymen
• Finding of size of testicle
• Finding of tone of female perineum
• Finding of tone of female perineum
• Finding of tone of female perineum
• Finding of vaginal liquor
• Finding of vaginal liquor
• Finding of vaginal liquor
• Genitourinary pain
• Genitourinary tenderness
• Genitourinary tract hemorrhage
• Goodell's sign
• Hegar's sign
• Hymenal orifice dilated
• Impaired urinary bladder capacity
• Impaired urinary system function
• Inappropriate erection
• Increased erection of penis
• Increased fertility
• Inequality in size of kidneys
• Kidney palpable
• Kidney palpable
• Kidney present
• Large testicle
• Lax female perineum
• Lesion of female perineum
• Maternity pad damp with liquor
• Maternity pad soaked with liquor
• Maternity pad wet with liquor
• Mottling
• Mottling of kidney
• Nocturnal erection of penis
• Palpable left kidney
• Palpable right kidney
• Patency of cervical os uteri - finding
• Perineal descent
• Perineal soiling
• Perineum button holing
• Perineum dirty
• Perineum dry
• Perineum edematous
• Perineum not stretching
• Perineum stretching
• Pneumatouria
• Porter colored urine
• Postcoital cervical mucus spermatozoa, rapid progressive motility
• Postcoital cervical mucus spermatozoa, slow progressive motility
• Postcoital cervical mucus, non-progressive motile and immotile spermatozoa
• Postcoital finding
• Postcoital finding
• Postcoital finding
• Prolonged erection of penis
• Pseudoemission
• Reddish color urine
• Rigid perineum
• Self-toileting deficit
• Single functional kidney
• Soft testes
• Sparseness of secondary sexual hair
• Spermatozoa absent
• Swelling of urogenital structure
• Tender testes
• Tenderness of male genital structure
• Tenderness of male genital structure
• Tense perineum
• Urinary tract pain
• Urinary tract tenderness
• Uterine souffle
• Vaginal liquor pad finding
• Vaginal liquor pad finding
• Vaginal liquor pad finding
• Vaginal pad finding
• Vaginal pad finding
• Vaginal pad finding
• Vas deferens tender
• Waking erection
• Wet dreams

Clinical Information

• Bladder Pain

  painful sensation in the bladder region.

• Gallbladder Pain, CTCAE 5.0|Gallbladder Pain|Gallbladder pain

  a disorder characterized by a sensation of marked discomfort in the gallbladder region.

• Gallbladder Pain|Gallbladder pain

  painful sensation in the gallbladder region.

• Grade 1 Gallbladder Pain, CTCAE|Grade 1 Gallbladder pain|Grade 1 Gallbladder pain

  mild pain

• Grade 2 Gallbladder Pain, CTCAE|Grade 2 Gallbladder pain|Grade 2 Gallbladder pain

  moderate pain; limiting instrumental adl

• Grade 3 Gallbladder Pain, CTCAE|Grade 3 Gallbladder pain|Grade 3 Gallbladder pain

  severe pain; limiting self care adl

• Uterine Souffle

  a soft murmur heard in auscultating a pregnant uterus. it is caused by the increased vascularity of pregnancy.

• Acute Bilineal Leukemia in Remission

  a finding of acute bilineal leukemia that is not growing and responds to treatment.

• Acute Erythroid Leukemia in Remission|Acute erythroid leukemia, in remission

  a finding of acute erythroid leukemia that is not growing and responds to treatment.

• Acute Erythroid Leukemia not Having Achieved Remission|Acute erythroid leukemia, not having achieved remission

  evidence of acute erythroid leukemia not having achieved remission.

• Acute Leukemia in Remission|Acute Leukemia (in Remission)|Acute leukemia of unspecified cell type, in remission

  a finding of acute leukemia that is not growing and responds to treatment.

• Acute Leukemia of Unspecified Cell Type not Having Achieved Remission|Acute leukemia of unspecified cell type not having achieved remission

  evidence of acute leukemia of unspecified cell type not having achieved remission.

• Acute Lymphoblastic Leukemia in Remission|ALL in Remission|Acute Lymphocytic Leukemia (in Remission)|Acute Lymphocytic Leukemia in Remission|Acute Lymphogenous Leukemia in Remission|Acute Lymphoid Leukemia in Remission|Acute lymphoblastic leukemia, in remission|Precursor Lymphoblastic Leukemia in Remission

  a finding of acute lymphoblastic leukemia that is not growing and responds to treatment.

• Acute Lymphoblastic Leukemia not Having Achieved Remission|Acute lymphoblastic leukemia not having achieved remission

  evidence of acute lymphoblastic leukemia not having achieved remission.

• Acute Megakaryoblastic Leukemia in Remission|Acute megakaryoblastic leukemia, in remission

  a finding of acute megakaryoblastic leukemia that is not growing and responds to treatment.

• Acute Megakaryoblastic Leukemia not Having Achieved Remission|Acute megakaryoblastic leukemia not having achieved remission

  evidence of acute megakaryoblastic leukemia not having achieved remission.

• Acute Monoblastic and Monocytic Leukemia in Remission|Acute monoblastic/monocytic leukemia, in remission

  a finding of acute monoblastic and monocytic leukemia that is not growing and responds to treatment.

• Acute Monoblastic and Monocytic Leukemia not Having Achieved Remission|Acute monoblastic/monocytic leukemia, not having achieved remission

  evidence of acute monoblastic and monocytic leukemia not having achieved remission.

• Acute Monocytic Leukemia in Remission|Acute Monocytic Leukemia (in Remission)|Monocytic Leukemia (in Remission)|Monocytic Leukemia in Remission|Monocytic leukemia, unspecified in remission

  a finding of acute monocytic leukemia that is not growing and responds to treatment.

• Acute Monocytic Leukemia, Unspecified not Having Achieved Remission|Monocytic leukemia, unspecified, not having achieved remission

  evidence of acute monocytic leukemia, not having achieved remission.

• Acute Myeloblastic Leukemia not Having Achieved Remission|Acute myeloblastic leukemia, not having achieved remission

  evidence of acute myeloblastic leukemia not having achieved remission.

• Acute Myeloid Leukemia in Remission|AML in Remission|ANLL in Remission|Acute Granulocytic Leukemia in Remission|Acute Myeloblastic Leukemia in Remission|Acute Myelocytic Leukemia in Remission|Acute Myelogenous Leukemia in Remission|Acute Myeloid Leukemia (in Remission)|Acute Non-Lymphoblastic Leukemia in Remission|Acute Non-Lymphocytic Leukemia in Remission|Acute Nonlymphoblastic Leukemia in Remission|Acute Nonlymphocytic Leukemia in Remission|Acute myeloblastic leukemia, in remission

  a finding of acute myeloid leukemia that is not growing and responds to treatment.

• Acute Myeloid Leukemia with MLL Rearrangement in Remission|Acute myeloid leukemia with 11q23 abnormality in remission

  a finding of acute myeloid leukemia with mll rearrangement that is not growing and responds to treatment.

• Acute Myeloid Leukemia with MLL Rearrangement not Having Achieved Remission|Acute myeloid leukemia with 11q23 abnormality not having achieved remission

  evidence of acute myeloid leukemia with mll rearrangement not having achieved remission.

• Acute Myeloid Leukemia with Multilineage Dysplasia in Remission|Acute myeloid leukemia with multilineage dysplasia, in remission

  a finding of acute myeloid leukemia with multilineage dysplasia that is not growing and responds to treatment.

• Acute Myeloid Leukemia with Multilineage Dysplasia not Having Achieved Remission|Acute myeloid leukemia with multilineage dysplasia not having achieved remission

  evidence of acute myeloid leukemia with multilineage dysplasia not having achieved remission.

• Acute Myelomonocytic Leukemia in Remission|Acute myelomonocytic leukemia, in remission

  a finding of acute myelomonocytic leukemia that is not growing and responds to treatment.

• Acute Myelomonocytic Leukemia not Having Achieved Remission|Acute myelomonocytic leukemia, not having achieved remission

  evidence of acute myelomonocytic leukemia not having achieved remission.

• Acute Panmyelosis with Myelofibrosis in Remission|Acute panmyelosis with myelofibrosis, in remission

  a finding of acute panmyelosis with myelofibrosis that is not growing and responds to treatment.

• Acute Panmyelosis with Myelofibrosis not Having Achieved Remission|Acute panmyelosis with myelofibrosis not having achieved remission

  evidence of acute panmyelosis with myelofibrosis not having achieved remission.

• Acute Promyelocytic Leukemia in Remission|Acute promyelocytic leukemia, in remission

  a finding of acute promyelocytic leukemia that is not growing and responds to treatment.

• Acute Promyelocytic Leukemia not Having Achieved Remission|Acute promyelocytic leukemia, not having achieved remission

  evidence of acute promyelocytic leukemia not having achieved remission.

• Adult Acute Lymphoblastic Leukemia in Remission|Acute Lymphoblastic Leukemia (ALL) in Remission|Adult ALL in Remission|Adult Acute Lymphocytic Leukemia in Remission|Adult Acute Lymphogenous Leukemia in Remission|Adult Acute Lymphoid Leukemia in Remission|Adult Precursor Lymphoblastic Leukemia in Remission

  a finding of acute lymphoblastic leukemia in adults that is not growing and responds to treatment.

• Adult Acute Myeloid Leukemia in Remission|Acute Myeloid Leukemia (AML) in Remission|Adult AML in Remission|Adult ANLL in Remission|Adult Acute Granulocytic Leukemia in Remission|Adult Acute Myeloblastic Leukemia in Remission|Adult Acute Myelogenous Leukemia in Remission|Adult Acute Non-Lymphoblastic Leukemia in Remission|Adult Acute Non-Lymphocytic Leukemia in Remission|Adult Acute NonLymphocytic Leukemia in Remission

  a finding of acute myeloid leukemia in adults that is not growing and responds to treatment.

• Adult T-Cell Leukemia/Lymphoma in Remission|Adult T-cell lymphoma/leukemia (HTLV-1-associated) in remission

  a finding of adult t-cell leukemia/lymphoma that is not growing and responds to treatment.

• Adult T-Cell Leukemia/Lymphoma not Having Achieved Remission|Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission

  evidence of adult t-cell leukemia/lymphoma not having achieved remission.

• Alcohol Abuse, in Remission|Alcohol abuse, in remission

  evidence of alcohol abuse, in remission.

• Alcohol Dependence, in Remission|Alcohol dependence, in remission

  evidence of alcohol dependence, in remission.

• Atypical Chronic Myeloid Leukemia, BCR-ABL Negative not Having Achieved Remission|Atypical chronic myeloid leukemia, BCR/ABL-negative not having achieved remission

  evidence of atypical chronic myeloid leukemia, bcr-abl negative not having achieved remission.

• Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative in Remission|Atypical chronic myeloid leukemia, BCR/ABL-negative, in remission

  a finding of atypical chronic myeloid leukemia, bcr-abl1 negative that is not growing and responds to treatment.

• B-Cell Prolymphocytic Leukemia in Remission|Prolymphocytic leukemia of B-cell type, in remission

  a finding of b-cell prolymphocytic leukemia that is not growing and responds to treatment.

• B-Cell Prolymphocytic Leukemia not Having Achieved Remission|Prolymphocytic leukemia of B-cell type not having achieved remission

  evidence of b-cell prolymphocytic leukemia not having achieved remission.

• Bipolar Disorder, Currently in Remission, Most Recent Episode Unspecified|Bipolar disorder, currently in remission, most recent episode unspecified

  evidence of bipolar disorder, currently in remission, most recent episode unspecified.

• Bipolar Disorder, in Full Remission, Most Recent Episode Depressed|Bipolar disorder, in full remission, most recent episode depressed

  evidence of bipolar disorder, in full remission, most recent episode depressed.

• Bipolar Disorder, in Full Remission, Most Recent Episode Hypomanic|Bipolar disorder, in full remission, most recent episode hypomanic

  evidence of bipolar disorder, in full remission, most recent episode hypomanic.

• Bipolar Disorder, in Full Remission, Most Recent Episode Manic|Bipolar disorder, in full remission, most recent episode manic

  evidence of bipolar disorder, in full remission, most recent episode manic.

• Bipolar Disorder, in Full Remission, Most Recent Episode Mixed|Bipolar disorder, in full remission, most recent episode mixed

  evidence of bipolar disorder, in full remission, most recent episode mixed.

• Bipolar Disorder, in Partial Remission, Most Recent Episode Depressed|Bipolar disorder, in partial remission, most recent episode depressed

  evidence of bipolar disorder, in partial remission, most recent episode depressed.

• Bipolar Disorder, in Partial Remission, Most Recent Episode Hypomanic|Bipolar disorder, in partial remission, most recent episode hypomanic

  evidence of bipolar disorder, in partial remission, most recent episode hypomanic.

• Bipolar Disorder, in Partial Remission, Most Recent Episode Manic|Bipolar disorder, in partial remission, most recent episode manic

  evidence of bipolar disorder, in partial remission, most recent episode manic.

• Bipolar Disorder, in Partial Remission, Most Recent Episode Mixed|Bipolar disorder, in partial remission, most recent episode mixed

  evidence of bipolar disorder, in partial remission, most recent episode mixed.

• Burkitt Leukemia in Remission|Mature B-cell leukemia Burkitt-type, in remission

  a finding of burkitt leukemia that is not growing and responds to treatment.

• Burkitt Leukemia not Having Achieved Remission|Mature B-cell leukemia Burkitt-type not having achieved remission

  evidence of burkitt leukemia not having achieved remission.

• C-11 Choline Positron Emission Tomography and Magnetic Resonance Imaging|C-11 Choline PET/MRI|C-11 Choline PET/MRI Scan

  an imaging procedure that combines c-11 choline pet with an mri scan to overlay activity data onto detailed anatomic images.

• Cannabis Abuse, in Remission|Cannabis abuse, in remission

  evidence of cannabis abuse, in remission.

• Cannabis Dependence, in Remission|Cannabis dependence, in remission

  evidence of cannabis dependence, in remission.

• Carbon-11 Choline Positron Emission Tomography|Choline Positron emission tomography

  a positron emission tomography imaging technique that uses c-11 choline to bind to cancer cells and locate cancer lesions.

• Childhood Acute Lymphoblastic Leukemia in Remission|Acute Lymphoblastic Leukemia (ALL) in Remission|Childhood ALL in Remission|Childhood Acute Lymphocytic Leukemia in Remission|Childhood Acute Lymphogenous Leukemia in Remission|Childhood Acute Lymphoid Leukemia in Remission|Childhood Precursor Lymphoblastic Leukemia in Remission|Pediatric ALL in Remission|Pediatric Acute Lymphoblastic Leukemia in Remission|Pediatric Acute Lymphocytic Leukemia in Remission|Pediatric Acute Lymphogenous Leukemia in Remission|Pediatric Acute Lymphoid Leukemia in Remission

  a finding of acute lymphoblastic leukemia in children that is not growing and responds to treatment.

• Childhood Acute Myeloid Leukemia in Remission|Acute Myeloid Leukemia (AML) in Remission|Childhood AML in Remission|Childhood Acute Granulocytic Leukemia in Remission|Childhood Acute Myeloblastic Leukemia in Remission|Childhood Acute Myelocytic Leukemia in Remission|Childhood Acute Myelogenous Leukemia in Remission|Pediatric AML in Remission|Pediatric Acute Granulocytic Leukemia in Remission|Pediatric Acute Myeloblastic Leukemia in Remission|Pediatric Acute Myelocytic Leukemia in Remission|Pediatric Acute Myelogenous Leukemia in Remission|Pediatric Acute Myeloid Leukemia in Remission

  a finding of acute myeloid leukemia of childhood that is not growing and responds to treatment.

• Childhood Myeloid Leukemia in Remission|Childhood Nonlymphocytic Leukemia in Remission|Myeloid Leukemia in Remission

  a finding of childhood myeloid leukemia that is not growing and responds to treatment.

• Childhood T Acute Lymphoblastic Leukemia in Remission|T Acute Lymphoblastic Leukemia in Remission

  a finding of t acute lymphoblastic leukemia in childhood that is not growing and responds to treatment.

• Chronic Leukemia in Remission|Chronic Leukemia (in Remission)|Chronic leukemia of unspecified cell type, in remission

  a finding of chronic leukemia that is not growing and responds to treatment.

• Chronic Leukemia of Unspecified Cell Type not Having Achieved Remission|Chronic leukemia of unspecified cell type not having achieved remission

  evidence of chronic leukemia of unspecified cell type not having achieved remission.

• Chronic Lymphocytic Leukemia in Remission|CLL in Remission|Chronic Lymphocytic Leukemia (CLL) in Remission|Chronic Lymphocytic Leukemia (in Remission)|Chronic Lymphogenous Leukemia in Remission|Chronic Lymphoid Leukemia in Remission|Chronic lymphocytic leukemia of B-cell type in remission

  a finding of chronic lymphocytic leukemia that is not growing and responds to treatment.

• Chronic Lymphocytic Leukemia of B-Cell Type not Having Achieved Remission|Chronic lymphocytic leukemia of B-cell type not having achieved remission

  evidence of chronic lymphocytic leukemia of b-cell type not having achieved remission.

• Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission|CML in Remission|Chronic Granulocytic Leukemia in Remission|Chronic Myelocytic Leukemia in Remission|Chronic Myelogenous Leukemia (CML) in Remission|Chronic Myelogenous Leukemia in Remission|Chronic Myeloid Leukemia (in Remission)|Chronic Myeloid Leukemia in Remission|Chronic myeloid leukemia, BCR/ABL-positive, in remission

  a finding of chronic myelogenous leukemia, bcr-abl1 positive that is not growing and responds to treatment.

• Chronic Myeloid Leukemia, BCR-ABL Positive, not Having Achieved Remission|Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission

  evidence of chronic myeloid leukemia, bcr-abl positive, not having achieved remission.

• Chronic Myelomonocytic Leukemia in Remission|CMML in Remission|Chronic Myelomonocytic Leukaemia (in Remission)|Chronic Myelomonocytic Leukemia (CMML) in Remission|Chronic myelomonocytic leukemia, in remission

  a finding of chronic myelomonocytic leukemia that is not growing and responds to treatment.

• Chronic Myelomonocytic Leukemia not Having Achieved Remission|Chronic myelomonocytic leukemia not having achieved remission

  evidence of chronic myelomonocytic leukemia not having achieved remission.

• Clinical Complete Response|Clinical Complete Remission|cCR|cCR

  the disappearance of all signs of cancer based on physical exam, such as palpation.

• Clinical Partial Response|Clinical Partial Remission|Partial|cPR|cPR

  a decrease in the size and the extent of tissue involvement by cancer, based on physical exam, such as palpation.

• Cocaine Abuse, in Remission|Cocaine abuse, in remission

  evidence of cocaine abuse, in remission.

• Cocaine Dependence, in Remission|Cocaine dependence, in remission

  evidence of cocaine dependence, in remission.

• Coke Oven Emission

  a complex mixture of dusts, vapors and gases that contains various known or potential carcinogens, including polycyclic aromatic hydrocarbons, formaldehyde, nitrosamines, coal tar and coal tar pitch, cadmium, benzene and arsenic compounds. coke oven emissions are produced during the conversion of coal into coke by heating the coal in the absence of oxygen. chronic exposure to coke oven emissions in humans results in conjunctivitis, severe dermatitis, and lesions in the respiratory and digestive-tract. coke oven emissions are associated with an increased risk of developing lung, skin, kidney and bladder cancer. (nci05)

• Coke Oven Emission Exposure|Coke Oven Emission|Coke ovens

  occupational exposure to gases and particulates produced when coal is processed in a coke oven.

• Complete Hematologic Response|CHR|CHR|Complete Hematologic Remission

  the disappearance of cancer in response to treatment, including platelet and white blood cell counts returning to normal levels, a non-palpable spleen, and no immature white blood cells present in the blood unless it is a regenerating marrow following treatment.

• Complete Remission in Acute Myeloid Leukemia with Partial Hematologic Recovery|Complete Remission with Partial Hematologic Recovery (CRh)

  an endpoint in the treatment of acute myeloid leukemia, defined as a finding of less than 5 percent bone marrow blasts, absolute neutrophil count greater than 500 cells per microliter, and platelet count greater than 50,000 cells per microliter.

• Complete Remission in Leukemia

  the disappearance of all signs of leukemia in response to treatment.

• Complete Remission with Incomplete Hematological Recovery|Complete Remission with Incomplete Hematologic Recovery|Complete Remission with Incomplete Hematological Recovery (CRi)

  the disappearance of all signs of leukemia in response to treatment with residual neutropenia (less than 1,000 per microliter), with or without complete platelet recovery.

• Complete Remission|CR|CR|CR-Complete Response|Cancer in complete remission(finding)|Cancer-Free|Complete Response|Complete Response|Complete Response|Complete Response|Complete Response|Complete Response|Complete Response|Complete Response|Complete Response|Complete response|complete remission|complete response

  the disappearance of all signs of cancer in response to treatment.

• Complete Response by Computed Tomography|CR-CT|CR-CT|Complete Remission, CT-Based|Complete Response, CT-Based

  the disappearance of all signs of cancer, based on ct scan and criteria-defined assessments.

• Complete Response with Incomplete Bone Marrow Recovery|CRi|Complete Remission with Incomplete Blood Count Recovery

  the disappearance of all signs of cancer in response to treatment accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.

• Consolidation Therapy|Consolidation|Consolidation|Consolidation|Consolidation|Consolidation|Post Remission Therapy|Postremission Therapy|consolidation therapy|intensification therapy|postremission therapy

  treatment that is given after initial therapy to kill any remaining cancer cells.

• Cytogenetic Complete Response|CCgR|CCgR|CCyR|CCyR|CRc|CRc|CYTOGENETIC CR|Complete Cytogenetic Response|Cytogenetic Complete Remission

  the disappearance of all signs of cancer, including the absence of a detectable disease-related genetic abnormality, as determined by techniques such as karyotyping or fish, in response to treatment.

• Death without Remission

  an indication that a subject died during treatment but had not achieved remission.

• Device Smoking|Smoke Emission|Smoking

  problem associated with a cloud of vapor or gas generated from the device, generally associated after a fire or a burn.

• Diffuse Large B-Cell Lymphoma in Complete Remission

  a finding of diffuse large b-cell lymphoma with no evidence of disease after therapy.

• Diffuse Large B-Cell Lymphoma in Partial Remission

  a finding of diffuse large b-cell lymphoma with some evidence of disease after therapy.

• Distortion Product Otoacoustic Emissions|DPOAE|DPOAE

  a neurologic test that provides a preneural, noninvasive assessment of cochlear function. distortion-product otoacoustic emissions are generated in the cochlea in response to two tones of a given frequency and sound pressure level presented in the ear canal and are an objective indicator of normally functioning cochlea outer hair cells.

• Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Positron Emission Tomography|DCE-MRI with PET|DCE-MRI/PET

  a type of multimodality imaging that combines dynamic contrast-enhanced mri with positron emission tomography for the simultaneous acquisition of both anatomic and functional images.

• Emission

  a substance that is emitted or released.

• Emission scan

  the usual mode of scanner operation in which a tracer's distribution throughout a subject is detected for subsequent processing into an image.

• Emission Spectrometer

  a spectrometer that applies some form of energy to a substance, thereby causing emission of electromagnetic radiation which is then quantified using a detector.

• Erythroleukemia in Remission

  a finding of erythroleukemia that is not growing and responds to treatment.

• Escape to Nostril with or without Emission During Swallowing|Escape to nostril with/without emission

  a finding of escape to nostril with or without emission during swallowing.

• Extraosseous Plasmacytoma in Remission|Extramedullary plasmacytoma in remission

  a finding of extraosseous plasmacytoma that is not growing and responds to treatment.

• Extraosseous Plasmacytoma not Having Achieved Remission|Extramedullary plasmacytoma not having achieved remission

  evidence of extraosseous plasmacytoma not having achieved remission.

• F-18 DCFPyL PSMA Positron Emission Tomography

  a positron emission tomography imaging technique that uses f-18 labelled dcfpyl to bind to prostate-specific membrane antigen-expressing tumor cells to locate cancer lesions.

• F-18 Fluciclovine Positron Emission Tomography and Computed Tomography|F-18 Fluciclovine PET/CT|F-18 Fluciclovine PET/CT Scan|PET-CT (F-18 fluciclovine)

  an imaging procedure that combines fluciclovine f18 pet with an computed tomography to overlay activity data onto detailed anatomic images.

• F-18 Fluciclovine Positron Emission Tomography and Magnetic Resonance Imaging|F-18 Fluciclovine PET/MRI|F-18 Fluciclovine PET/MRI Scan

  an imaging procedure that combines fluciclovine f18 pet with an mri scan to overlay activity data onto detailed anatomic images.

• F-18 Fluciclovine Positron Emission Tomography|Fluciclovine - Positron emission tomography

  a positron emission tomography imaging technique that uses f-18 fluciclovine to bind to cancer cells and locate cancer lesions.

• F-18 Sodium Fluoride Positron Emission Tomography and Computed Tomography Scan|F-18 Sodium Fluoride PET/CT

  an imaging procedure that combines f-18 sodium fluoride pet with a ct scan to overlay activity data onto detailed anatomic images.

• F-18 Sodium Fluoride Positron Emission Tomography and Magnetic Resonance Imaging|F-18 Sodium Fluoride PET/MRI|F-18 Sodium Fluoride PET/MRI Scan

  an imaging procedure that combines f-18 sodium fluoride pet with an mri scan to overlay activity data onto detailed anatomic images.

• F-18 Sodium Fluoride Positron Emission Tomography|F 18 sodium fluoride positron emission tomography|F-18 NaF PET|F-18 Sodium Fluoride Positron Emission Tomography and Computed Tomography Scan|fluorine F 18 sodium fluoride PET

  computed tomography that uses f[18] as a positron source for 3-dimensional imaging.

• Factory Smokestack Smoke Exposure|Factory Smokestack Emission Exposure|Factory smokestack smoke

  environmental or occupational exposure to airborne gases and particulates emitted by a factory smokestack.

• Failure to Attain Remission

  remission status was not attained.

• FDG-Positron Emission Tomography and Computed Tomography Scan|FDG PET/CT

  an imaging procedure that combines fdg pet with a ct scan to overlay activity data onto detailed anatomic images.

• FDG-Positron Emission Tomography/Computed Tomography from the Skull Base to Mid-thigh|FDG PET/CT Skull Base to Mid-thigh|PET/CT, Skull Base to Mid-thigh, FDG|Positron Emission Tomography/Computed Tomography, Skull Base to Mid-thigh, FDG|Skull Base to Mid-thigh 18F FDG PET/CT|Skull Base to Mid-thigh FDG-PET/CT|Skull Base to Mid-thigh FDG-Positron Emission Tomography/Computed Tomography|Skull Base to Mid-thigh PET/CT Scan with FDG

  positron emission tomography combined with computed tomography of the region encompassing the skull base to the mid-thigh with the use of the contrast agent fludeoxyglucose f 18 (18f-fdg) to enhance the image.

• FDG-Positron Emission Tomography/Computed Tomography of an Area of Interest|Area of Interest 18F FDG PET/CT|Area of Interest FDG-PET/CT|Area of Interest FDG-Positron Emission Tomography/Computed Tomography|FDG PET/CT Area of Interest|PET/CT, Area of Interest, FDG|Positron Emission Tomography/Computed Tomography, Area of Interest, FDG

  positron emission tomography combined with computed tomography of an anatomical area of interest with the use of the contrast agent fludeoxyglucose f 18 (18f-fdg) to enhance the image.

• FDG-Positron Emission Tomography/Computed Tomography of the Whole Body|EXPLORER Scanner|PET/CT, Whole Body, FDG|Positron Emission Tomography/Computed Tomography, Whole Body, FDG|Total-Body Positron Emission Tomography/Computed Tomography|WB PET/CT Scan with FDG|Whole Body FDG-PET/CT|Whole Body FDG-Positron Emission Tomography/Computed Tomography|Whole Body [18]F- Fludeoxyglucose Positron Emission Tomography/Computed Tomography|Whole-body 18F FDG PET/CT|Whole-body FDG-PET/CT|[18]F-FDG PET/CT

  positron emission tomography combined with computed tomography of the whole body, with the use of the contrast agent fludeoxyglucose f 18 (18f-fdg) to enhance the image.

• FDG-Positron Emission Tomography|FDG|FDG-PET|FDG-PET|FDG-PET Imaging

  an imaging technique that utilizes positron emission tomography to produce a three-dimensional image of functional processes in the body. the system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on the biologically active molecule (fludeoxyglucose) fdg. fdg is an analogue of glucose which when imaged will give tissue metabolic activity, in terms of regional glucose uptake.

• FLT-Positron Emission Tomography|FLT-PET|Fluoro-L-Thymidine-Positron Emission Tomography

  an imaging technique that utilizes positron emission tomography to produce a three-dimensional image of functional processes in the body. the system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (tracer), which is introduced into the body on the biologically active molecule fluoro-l-thymidine (flt). flt when imaged will give tissue metabolic activity, in terms of cell proliferation.

• Fluorine F 18 Fluoro Furanyl Norprogesterone Positron Emission Tomography and Computed Tomography|FFNP PET-CT|FFNP PET-CT Scan|FFNP-PET/CT

  an imaging procedure that combines fluoro-furanyl-norprogesterone f18 pet with computed tomography to quantitate progesterone receptor (pgr) status in pgr-positive breast cancers.

• Ga-68 NeoBOMB1 PET/MRI Positron Emission Tomography and Magnetic Resonance Imaging|68Ga NeoBOMB1 PET/MRI|Ga-68 NeoBOMB1 PET/MRI|Gallium Ga 68-NeoB PET/MRI|Gallium Ga-68 NeoBOMB1 PET/MRI

  an imaging procedure that combines gallium-68-labelled neobomb1 pet with an mri scan to overlay activity data onto detailed anatomic images.

• Ga-68 PET/CT Scan|Gallium-68 PET/CT Scan|Gallium-68 Positron Emission Tomography and Computed Tomography Scan

  a positron emission tomography and computed tomography scan that uses a gallium-68 labeled marker.

• Ga-68 PSMA-R2 Positron Emission Tomography and Magnetic Resonance Imaging|68Ga PSMA-R2 PET/MRI|Ga-68 PSMA-R2 PET/MRI|Gallium Ga-68 PMSA-R2 PET/MRI

  an imaging procedure that combines gallium-68-labelled psma-r2 with an mri scan to overlay activity data onto detailed anatomic images.

• Hairy Cell Leukemia in Remission|Hairy cell leukemia, in remission

  a finding of hairy cell leukemia that is not growing and responds to treatment.

• Hairy Cell Leukemia not Having Achieved Remission|Hairy cell leukemia not having achieved remission

  evidence of hairy cell leukemia not having achieved remission.

• Hallucinogen Abuse, in Remission|Hallucinogen abuse, in remission

  evidence of hallucinogen abuse, in remission.

• Hallucinogen Dependence, in Remission|Hallucinogen dependence, in remission

  evidence of hallucinogen dependence, in remission.

• Hodgkin Lymphoma in Remission

  a finding of hodgkin lymphoma that is not growing and responds to treatment.

• Immuno-Positron Emission Tomography Scan|IMMUNO-PET SCAN|Immuno-PET Scan

  a type of positron emission tomography in which labeled monoclonal antibodies are tracked and quantitated after administration to the subject.

• Inductively-Coupled Plasma Optical Emission Spectrometer|ICP Optical Emission Spectrometer

  a spectrometer in which a sample is introduced, either by spraying or ultrasonic nebulization, into inductively-coupled plasma generated from argon gas. this process excites dissolved metals, thereby causing them to emit radiation in both the uv and visible spectrum. the emitted radiation is dispersed by a grating monochrometer and detected with photomultiplier tubes.

• Inhalant Abuse, in Remission|Inhalant abuse, in remission

  evidence of inhalant abuse, in remission.

• Inhalant Dependence, in Remission|Inhalant dependence, in remission

  evidence of inhalant dependence, in remission.

• IWG-MRT Myelofibrosis Complete Remission

  bone marrow: age-adjusted normocellularity; less than 5 percent blasts; less than or equal to grade 1 myelofibrosis and peripheral blood: hemoglobin greater than or equal to 100 g/l and less than upper normal limit; neutrophil count greater than or equal 1x10^9/l and less than upper normal limit; platelet count greater or equal to 100x10^9/l and less than upper normal limit; less than 2 percent immature myeloid cells and clinical: resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis (adapted from revised response criteria for myelofibrosis: international working group-myeloproliferative neoplasms research and treatment (iwg-mrt) and european leukemianet (eln) consensus report. blood 22 august 2013 x volume 122 number 8)

• IWG-MRT Myelofibrosis Cytogenetic Remission

  at least 10 metaphases must be analyzed for cytogenetic response evaluation and requires confirmation by repeat testing within 6 months window. complete response: eradication of a preexisting abnormality. partial response: greater than or equal to 50 percent reduction in abnormal metaphases. (partial response applies only to patients with at least ten abnormal metaphases at baseline) (adapted from revised response criteria for myelofibrosis: international working group-myeloproliferative neoplasms research and treatment (iwg-mrt) and european leukemianet (eln) consensus report. blood 22 august 2013 x volume 122 number 8)

• IWG-MRT Myelofibrosis Molecular Remission

  molecular response evaluation must be analyzed in peripheral blood granulocytes and requires confirmation by repeat testing within 6 months window. complete response: eradication of a pre-existing abnormality. partial response: greater than or equal to 50 percent decrease in allele burden (partial response applies only to patients with at least 20 percent mutant allele burden at baseline.) (adapted from revised response criteria for myelofibrosis: international working group-myeloproliferative neoplasms research and treatment (iwg-mrt) and european leukemianet (eln) consensus report. blood 22 august 2013 x volume 122 number 8)

• IWG-MRT Myelofibrosis Partial Remission

  peripheral blood: hemoglobin greater than or equal to 100 g/l and less than upper normal limit; neutrophil count greater than or equal to 1x10^9/l and less than upper normal limit; platelet count greater than or equal to 100x10^9/l and less than upper normal limit; less than 2 percent immature myeloid cells and clinical: resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis or bone marrow: age-adjusted normocellularity; less than 5 percent blasts; less than grade 1 myelofibrosis and peripheral blood: hemoglobin greater than or equal to 85 but less than 100 g/l and less than upper normal limit; neutrophil count greater than 1x10^9/l and less than upper normal limit; platelet count greater than or equal to 50 but less than 100x10^9/l and less than upper normal limit; less than 2 percent immature myeloid cells and clinical: resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis(adapted from revised response criteria for myelofibrosis: international working group-myeloproliferative neoplasms research and treatment (iwg-mrt) and european leukemianet (eln) consensus report. blood 22 august 2013 x volume 122 number 8)

• Juvenile Myelomonocytic Leukemia in Remission|Juvenile myelomonocytic leukemia, in remission

  juvenile myelomonocytic leukemia which is not growing and responds to treatment.

• Juvenile Myelomonocytic Leukemia not Having Achieved Remission|Juvenile myelomonocytic leukemia not having achieved remission

  evidence of juvenile myelomonocytic leukemia not having achieved remission.

• Leukemia in Remission|Leukemia (in Remission)|Leukemia, unspecified, in remission

  a finding of leukemia that is not growing and responds to treatment

• Leukemia, Unspecified not Having Achieved Remission|Leukemia, unspecified not having achieved remission

  evidence of leukemia, unspecified not having achieved remission.

• Lugano Lymphoma Response Classification Complete Remission by CT|CR|Complete Remission

  target nodes/nodal masses must regress to less than or equal to 1.5 cm in the longest transverse diameter. complete disappearance of radiologic evidence of disease. no extralymphatic sites of disease. organ enlargement regress to normal. bone marrow normal by morphology; if indeterminate, ihc negative.

• Lugano Lymphoma Response Classification Complete Remission by PET|CR|Complete Remission

  a score of 1, 2, or 3 on a 5-point pet scale in nodal or extranodal sites with or without a residual mass. no evidence of fdg-avid disease in the marrow.

• Lugano Lymphoma Response Classification Partial Remission by CT|PR|Partial Remission

  for multiple lesions, greater than or equal to 50 percent decrease in the sum of the product of the perpendicular diameters of up to six target measurable nodes and extranodal sites. if only a single lesion is present, greater than or equal to 50 percent decrease in the cross product of the longest transverse diameter and perpendicular diameter.. spleen must have regressed by >50% in length beyond normal" to the definition.

• Lugano Lymphoma Response Classification Partial Remission by PET|PR|Partial Remission

  a score of 4 or 5 on a 5-point pet scale with reduced uptake compared with baseline and residual mass(es) of any size. residual uptake higher than uptake in normal marrow but reduced compared to baseline.

• Lymphoid Leukemia in Remission|Lymphoid Leukemia (in Remission)|Lymphoid leukemia, unspecified, in remission

  a finding of lymphoid leukemia that is not growing and responds to treatment..

• Lymphoid Leukemia, Unspecified not Having Achieved Remission|Lymphoid leukemia, unspecified not having achieved remission

  evidence of lymphoid leukemia, unspecified not having achieved remission.

• Lymphoma in Remission

  a finding of lymphoma that is not growing and responds to treatment.

• Major Depressive Disorder, Recurrent, in Full Remission|Major depressive disorder, recurrent, in full remission

  evidence of major depressive disorder that is recurrent and in full remission.

• Major Depressive Disorder, Recurrent, in Partial Remission|Major depressive disorder, recurrent, in partial remission

  evidence of major depressive disorder that is recurrent and in partial remission.

• Major Depressive Disorder, Recurrent, in Remission, Unspecified|Major depressive disorder, recurrent, in remission, unspecified

  evidence of major depressive disorder that is recurrent and in remission.

• Major Depressive Disorder, Single Episode, in Full Remission|Major depressive disorder, single episode, in full remission

  evidence of major depressive disorder that is a single episode and is in full remission.

• Major Depressive Disorder, Single Episode, in Partial Remission|Major depressive disorder, single episode, in partial remission

  evidence of major depressive disorder that is a single episode and is in partial remission.

• Manic Episode in Full Remission|Manic episode in full remission

  evidence of manic episode in full remission.

• Manic Episode in Partial Remission|Manic episode in partial remission

  evidence of manic episode in partial remission.

• Marrow Complete Response|Marrow CR|Marrow Complete Remission|mCR|mCR

  a decrease in the number of bone marrow plasma cells to protocol-defined level(s).

• Mast Cell Leukemia in Remission|Mast cell leukemia, in remission

  a finding of mast cell leukemia that is not growing and responds to treatment.

• Mast Cell Leukemia not Having Achieved Remission|Mast cell leukemia not having achieved remission

  evidence of mast cell leukemia not having achieved remission.

• Modified Overall Immune Related Response Criterion, Complete Remission|Modified irCR

  the evaluation of the antitumor response shows a complete disappearance of all lesions (whether measurable or not) and no new lesions. all measurable lymph nodes also have a reduction in short axis diameter to 10 mm.

• Molecular Complete Response|CMR|Complete Molecular Response|MOLECULAR CR|Molecular CR|Molecular Complete Remission

  the disappearance of all signs of cancer, supported by molecular analysis.

• Monocytic Leukemia in Remission|Monocytic Leukemia (in Remission)

  monocytic leukemia responding to treatment and not proliferating

• Morphologic Complete Remission with Incomplete Blood Count Recovery|MORPHOLOGIC CRi|Morphologic CRi|Morphologic Complete Remission with Incomplete Bone Marrow Recovery

  the disappearance of all cells with morphologic characteristics of cancer, accompanied by incomplete bone marrow recovery, as evidenced by persistent anemia, thrombocytopenia or neutropenia.

• Morphologic Complete Response|MORPHOLOGIC CR|Morphologic CR|Morphologic Complete Remission

  the disappearance of all signs of cancer, supported by morphological analysis.

• Multiple Myeloma in Remission|Multiple myeloma in remission|Plasma Cell Myeloma in Remission

  a finding of plasma cell myeloma that is not growing and responds to treatment.

• Multiple Myeloma not Having Achieved Remission|Multiple myeloma not having achieved remission|Plasma Cell Myeloma not Having Achieved Remission

  evidence of plasma cell myeloma not having achieved remission.

• Myeloid Leukemia in Remission|Myelocytic Leukemia in Remission|Myelogenous Leukemia in Remission|Myeloid leukemia, unspecified in remission

  a finding of myeloid leukemia that is not growing and responds to treatment.

• Myeloid Leukemia, Unspecified, not Having Achieved Remission|Myeloid leukemia, unspecified, not having achieved remission

  evidence of myeloid leukemia, unspecified, not having achieved remission.

• Myeloid Sarcoma in Remission|Chloroma (in Remission)|Chloroma in Remission|Myeloid sarcoma, in remission

  a finding of myeloid sarcoma that is not growing and responds to treatment.

• Myeloid Sarcoma not Having Achieved Remission|Myeloid sarcoma, not having achieved remission

  evidence of myeloid sarcoma not having achieved remission.

• NCCN ALL Response Criteria for Blood and Bone Marrow Complete Remission

  no circulating lymphoblasts or extramedullary disease, trilineage hematopoiesis (tlh) and less than 5 percent blasts, anc greater than 1,000 per microl, platelets greater than 100,000 per microl, no recurrence for 4 weeks. (adapted from nccn guidelines, version 1.2020, february 20,2020)

• NCCN ALL Response Criteria for Blood and Bone Marrow Complete Remission with Incomplete Blood Count Recovery

  meets all criteria for nccn all complete response except platelet count or anc. (adapted from nccn guidelines, version 1.2020, february 20,2020)

• NCCN ALL Response Criteria for CNS Disease CNS Remission

  achievement of cns-1 status in a patient with cns-2 or cns-3 status at study entry. (adapted from nccn guidelines, version 1.2020, february 20, 2020)

• NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Complete Remission

  complete resolution of lymphomatous enlargement by ct. for patients with a previous positive pet scan, a post-treatment residual mass of any size is considered a cr as long as it is pet negative. (adapted from nccn guidelines, version 1.2020, february 20, 2020)

• NCCN ALL Response Criteria for Lymphomatous Extramedullary Disease Partial Remission

  greater than 50 percent disease in the sum of product of greatest perpendicular diameters (spd) of the mediastinal enlargement for patients with a previous positive pet scan, post-treatment pet must be positive in at least one previously involved site. (adapted from nccn guidelines, version 1.2020, february 20, 2020)

• Nephrotic Syndrome-Remission, Partial Remission|Partial Remission Nephrotic Syndrome Remission

  nephrotic syndrome in which proteinuria has decreased by at least 50% and below the nephrotic range cutoff from disease onset, but does not normalize following a defined course of treatment.

• Nodular Partial Remission|Nodular Partial Response|Nodular Partial Response|nPR

  remission with persistent lymphoid nodules in the bone marrow.

• Non-FDG-Positron Emission Tomography|Non-FDG-PET|Non-Fluoro-2-deoxy-D-glucose- Positron Emission Tomography

  positron emission tomography that uses a tracer other than fluoro-2-deoxy-d-glucose (fdg).

• Non-Hodgkin Lymphoma in Remission

  a finding of non-hodgkin lymphoma that is not growing and responds to treatment.

• Opioid Abuse, in Remission|Opioid abuse, in remission

  evidence of opioid abuse, in remission.

• Opioid Dependence, in Remission|Opioid dependence, in remission

  evidence of opioid dependence, in remission.

• Optical Emission Spectrometer|OE Spectrometer

  an emission spectrometer that generates a high-energy spark across an argon-filled gap between an electrode and a solid sample, causing emission of radiation from the excited sample surface and resulting in wavelengths characteristic of the elemental composition.

• Other Acute Monocytic Leukemia in Remission|Other monocytic leukemia, in remission

  evidence of other acute monocytic leukemia in remission not specified elsewhere.

• Other Acute Monocytic Leukemia not Having Achieved Remission|Other monocytic leukemia, not having achieved remission

  evidence of other acute monocytic leukemia not having achieved remission not specified elsewhere.

• Other Lymphoid Leukemia not Having Achieved Remission|Other lymphoid leukemia not having achieved remission

  evidence of other lymphoid leukemia not having achieved remission not specified elsewhere.

• Other Lymphoid Leukemia, in Remission|Other lymphoid leukemia, in remission

  evidence of other lymphoid leukemia in remission not specified elsewhere.

• Other Myeloid Leukemia in Remission|Other myeloid leukemia, in remission

  evidence of other myeloid leukemia in remission not specified elsewhere.

• Other Myeloid Leukemia not Having Achieved Remission|Other myeloid leukemia not having achieved remission

  evidence of other myeloid leukemia not having achieved remission not specified elsewhere.

• Other Psychoactive Substance Abuse, in Remission|Other psychoactive substance abuse, in remission

  evidence of other psychoactive substance abuse, in remission not specified elsewhere.

• Other Psychoactive Substance Dependence, in Remission|Other psychoactive substance dependence, in remission

  evidence of other psychoactive substance dependence, in remission not specified elsewhere.

• Other Specified Leukemias not Having Achieved Remission|Other specified leukemias not having achieved remission

  evidence of other specified leukemias not having achieved remission not specified elsewhere.

• Other Specified Leukemias, in Remission|Other specified leukemias, in remission

  evidence of other specified leukemias, in remission not specified elsewhere.

• Other Stimulant Abuse, in Remission|Other stimulant abuse, in remission

  evidence of other stimulant abuse, in remission not specified elsewhere.

• Other Stimulant Dependence, in Remission|Other stimulant dependence, in remission

  evidence of other stimulant dependence, in remission not specified elsewhere.

• Otoacoustic Emission|OAE

  an assessment of the otoacoustic sound emissions from the cochlea when stimulated by soft clicking sounds introduced into the ear canal.

• Partial Remission|Cancer in partial remission (finding)|PR|PR|PR-Partial Response|Partial Response|Partial Response|Partial Response|Partial Response|Partial Response|Partial Response|Partial Response|Partial Response|Partial Response|Partial Response|Partial Response|Partial response|partial remission|partial response

  a finding indicating that there is a decrease in the size and the extent of tissue involvement by a malignant tumor in a patient.

• Partial Response by Computed Tomography|PR-CT|PR-CT|Partial Remission, CT-Based|Partial Response, CT-Based

  a decrease in the size and extent of tissue involvement by cancer, based on ct scan and criteria-defined assessments.

• Pathologic Complete Response|Complete Pathological Response|Pathologic Complete Remission|Pathological Complete Remission|pCR|pCR

  the disappearance of all signs of cancer, supported by pathological examination.

• Photobiomodulation Therapy|Cold Laser Therapy|LLLT|Low Emission Laser Therapy|Low Level Laser Therapy|Low-Emission Laser Therapy

  a form of light therapy that utilizes non-ionizing light sources, including lasers, light emitting diodes, and/or broadband light, in the visible (400-700nm) and near-infrared (7001100nm) electromagnetic spectrum. it is a nonthermal process that leads to a cellular response mediated by mitochondrial mechanisms that reduce pain and inflammation and speed healing.

• Plasma Cell Leukemia in Remission|Leukemia Plasmacytic (in Remission)|Plasma cell leukemia in remission|Plasmacytic Leukemia (in Remission)|Plasmacytic Leukemia in Remission

  a finding of plasma cell leukemia that is not growing and responds to treatment.

• Plasma Cell Leukemia not Having Achieved Remission|Plasma cell leukemia not having achieved remission

  evidence of plasma cell leukemia not having achieved remission.

• Plasma Cell Neoplasm in Remission

  a finding of plasma cell neoplasm that is not growing and responds to treatment.

• Positron Emission Mammography

  an imaging technique that utilizes a radiolabeled sugar given intravenously to help define the size, shape, and location of a breast tumor.

• Positron Emission Tomography and Computed Tomography Scan|PET-CT Scan|PET-CT Scan|PET/CT SCAN|Positron Emission Tomography/Computed Tomography

  an imaging technique that utilizes positron emission tomography and computed tomography in a single machine.

• Positron Emission Tomography and Magnetic Resonance Imaging|PET-MRI Scan|PET/MRI|PET/MRI SCAN|Positron Emission Tomography/Magnetic Resonance Imaging Hybrid Imaging

  an imaging technique that utilizes positron emission tomography and magnetic resonance imaging in a single machine.

• Positron Emission Tomography and Single Photon Emission Computed Tomography Scan|PET/SPECT SCAN

  an imaging technique that utilizes positron emission tomography and single-photon emission computed tomography in a single machine.

• Positron Emission Tomography Drug Production|PET Drug Production|POSITRON EMISSION TOMOGRAPHY DRUG PRODUCTION

  the activity of producing any reagents used in positron emission tomography (pet) diagnostic imaging, including radioactive nuclides, nonradioactive reagent, reagent kit etc.

• Positron Emission Tomography with Radiolabeled Targeting Agent|Positron Emission Tomography with Radiolabeled Targeting Agents

  a functional nuclear medicine test that utilizes a radioactive tracer, most commonly the radiolabeled sugar fluorodeoxyglucose, to identify tumors and metastasis.

• Positron Emission Tomography|Medical Imaging, Positron Emission Tomography|PET|PET|PET SCAN|PET Scan|PET Scan|PET Scan|PET scan|PT|Pet Scan|Positron Emission Tomography Scan|Positron emission tomography (procedure)|Positron-Emission Tomography|positron emission tomography scan|proton magnetic resonance spectroscopic imaging

  a technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. in positron emission tomography (pet), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-d-glucose (fdg), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). when living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.

• PSMA PET Scan|PSMA PET|PSMA-Positron emission tomography|Prostate-specific Membrane Antigen PET

  a positron emission tomography imaging technique that uses the pet-sensitive drug, 68ga-psma-11, to bind to cancer cells and locate cancer lesions.

• Pure Erythroid Leukemia in Remission

  a finding of pure erythroid leukemia that is not growing and responds to treatment.

• Remission CALGB Criteria|N/A-Remission

  a rating for aml by calgb which indicates the patient has met the calgb criteria for remission.

• Remission|N/A - Remission|remission

  an abatement in intensity or degree (as in the manifestations of a disease).

• Sedative, Hypnotic or Anxiolytic Abuse, in Remission|Sedative, hypnotic or anxiolytic abuse, in remission

  evidence of sedative, hypnotic or anxiolytic abuse, in remission.

• Sedative, Hypnotic or Anxiolytic Dependence, in Remission|Sedative, hypnotic or anxiolytic dependence, in remission

  evidence of sedative, hypnotic or anxiolytic dependence, in remission.

• Single Photon Emission Computed Tomography|Medical Imaging, Single Photon Emission Computed Tomography|SPECT|SPECT|SPECT SCAN|SPECT imaging|SPET|ST|Single Photon Emission Tomography|Single-Photon Emission Computed|Tomography, Emission-Computed, Single-Photon|single-photon emission computed tomography|tomography, emission computed, single photon

  a type of tomography in which gamma photon-emitting radionuclides are administered to the patient and then detected by one or more gamma cameras rotated around the patient. from the series of two-dimensional images produced, a three-dimensional image can be created by computer reconstruction.

• Sodium Fluoride Positron Emission Tomography/Computed Tomography from the Skull Base to Mid-thigh|18F-NaF Skull Base to Mid-thigh PET/CT Scan|PET/CT, Skull Base to Mid-thigh, Sodium Fluoride|Positron Emission Tomography/Computed Tomography, Skull Base to Mid-thigh, Sodium Fluoride|Skull Base to Mid-thigh 18F-NaF Positron Emission Tomography/Computed Tomography|Skull Base to Mid-thigh PET/CT Scan with Sodium Fluoride|Skull Base to Mid-thigh Sodium Fluoride Positron Emission Tomography/Computed Tomography

  positron emission tomography combined with computed tomography of the region encompassing the skull base to the mid-thigh with the use of the contrast agent sodium fluoride f 18 (18f-naf) to enhance the image.

• Sodium Fluoride Positron Emission Tomography/Computed Tomography of the Whole Body|18F-NaF Whole-body PET/CT Scan|NaF PET/CT WB|PET/CT, Whole Body, Sodium Fluoride|Sodium Fluoride WB PET-CT|WB PET/CT Scan with Sodium Fluoride|Whole Body 18F-NaF Positron Emission Tomography/Computed Tomography|Whole Body Sodium Fluoride Positron Emission Tomography/Computed Tomography

  positron emission tomography combined with computed tomography of the whole body with the use of the contrast agent sodium fluoride f 18 (18f-naf) to enhance the image.

• Solitary Plasmacytoma in Remission|Solitary plasmacytoma in remission

  a finding of solitary plasmacytoma that is not growing and responds to treatment.

• Solitary Plasmacytoma not Having Achieved Remission|Solitary plasmacytoma not having achieved remission

  evidence of solitary plasmacytoma not having achieved remission.

• Stringent Complete Response|Stringent Complete Remission|sCR|sCR|sCR-Stringent Complete Response

  the confirmed disappearance of all signs of cancer, and absence of molecular or cytogenetic marker of disease, in response to treatment with additional biochemical, immunological and histopathological analyses to verify the cr.

• T-Cell Prolymphocytic Leukemia in Remission|Prolymphocytic leukemia of T-cell type, in remission

  a finding of t-cell prolymphocytic leukemia that is not growing and responds to treatment.

• T-Cell Prolymphocytic Leukemia not Having Achieved Remission|Prolymphocytic leukemia of T-cell type not having achieved remission

  evidence of t-cell prolymphocytic leukemia not having achieved remission.

• Transient Evoked Otoacoustic Emissions|TEOAE|TEOAE|TOAE|Transient Otoacoustic Emissions

  a non-invasive test of outer hair cell function up to 14.7 khz. otoacoustic emissions are measured by presenting a series of sounds to the ear through a probe that is inserted in the ear canal. the probe contains a loudspeaker that generates the sounds and a microphone that measures the resulting oaes that are produced in the cochlea and are transmitted through the middle ear into the outer ear canal.

• Unintended Emission

  problems due to unintended emission of electromagnetic energy by the device.

• Very Good Partial Response|VGPR|VGPR|VGPR-Very Good Partial Response|Very Good Partial Remission

  partial response with additional serum and urine m-protein reduction, but not meeting complete response.

• Wet Dream|Nocturnal Emission

  an involuntary ejaculation of semen accompanying an erotic dream.

R39.89 is grouped with Diagnostic Related Groups - MS-DRG Mapping

Diagnostic Related Groups (DRGs) are a classification system used to group together diagnosis codes for the purpose of reimbursement and healthcare management. DRGs are used to standardize the way hospitals and other providers are paid for inpatient services. In this system patients are grouped together based on their principal diagnosis in areas referred to as Major Diagnostic Categories (MDC). Once a patient is assigned a particular diagnostic category, providers receive a predetermined payment rate for the services rendered. This reimbursement rate is often fixed and is meant to cover the cost of care for that patient. Reimbursement is also affected by the relative weight of a diagnostic related group based on the severity of a patient's illness and the associated cost of care during hospitalization.

Diagnostic related groups encourage healthcare providers to focus on quality and efficiency in patient care while managing costs effectively. The diagnosis code is present in the following groups for version MS-DRG V41.0 applicable from 10/01/2023 through 09/30/2024.

The relative weight of a diagnostic related group determines the reimbursement rate based on the severity of a patient's illness and the associated cost of care during hospitalization.

Convert R39.89 to ICD-9-CM

• ICD-9-CM Code: 788.99 - Oth symptm urinary systm
  Approximate Flag - The approximate mapping means there is not an exact match between the ICD-10 and ICD-9 codes and the mapped code is not a precise representation of the original code.

Patient Education

Urine and Urination

Your kidneys make urine by filtering wastes and extra water from your blood. The waste is called urea. Your blood carries it to the kidneys. From the kidneys, urine travels down two thin tubes called ureters to the bladder. The bladder stores urine until you are ready to urinate. It swells into a round shape when it is full and gets smaller when empty. If your urinary system is healthy, your bladder can hold up to 16 ounces (2 cups) of urine comfortably for 2 to 5 hours.

You may have problems with urination if you have:

• Kidney failure
• Urinary tract infections
• An enlarged prostate
• Bladder control problems like incontinence, overactive bladder, or interstitial cystitis
• A blockage that prevents you from emptying your bladder

Some conditions may also cause you to have blood or protein in your urine. If you have a urinary problem, see your health care provider. Urinalysis and other urine tests can help to diagnose the problem. Treatment depends on the cause.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Code History

• FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
• FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
• FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
• FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
• FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
• FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
• FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
• FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
• FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.